EMA/699550/2021

European Medicines Agency decision

P/0537/2021

of 9 December 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for exebacase (EMEA-002947-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0537/2021

of 9 December 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for exebacase (EMEA-002947-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by ContraFect Corporation on 18 December 2020 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 November 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for exebacase, solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for exebacase, solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to ContraFect Corporation, 28 Wells Avenue, 3rd Floor, Yonkers, NY10701 - New York, United States.

EMA/PDCO/454802/2021
Amsterdam, 12 November 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-002947-PIP01-20

Scope of the application

Active substance(s):

Exebacase

Condition(s):

Treatment of *Staphylococcus aureus* bacteraemia

Pharmaceutical form(s):

Solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

ContraFect Corporation

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, ContraFect Corporation submitted for agreement to the European Medicines Agency on 18 December 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 26 January 2021.

Supplementary information was provided by the applicant on 5 August 2021. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of *Staphylococcus aureus* bacteraemia

2.1.1. Indication(s) targeted by the PIP

Treatment of *Staphylococcus aureus* bacteraemia in the setting of right-sided endocarditis, skin and soft tissue, intravascular and/or bone and joint infections, used in addition to standard-of-care antistaphylococcal antibiotics in all paediatric age ranges (0 to <18 years)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for infusion

2.1.4. Measures

Area	**Number of measures**	**Description**
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable
Clinical studies	2	**Study 1** Double-blind, randomised, placebo-controlled trial to evaluate pharmacokinetics, safety and efficacy of single dose of exebacase as add-on to standard of care compared to placebo in children from 12 years to less than 18 years of age (and adults) with *Staphylococcus aureus* blood stream infections **Study 2** Investigator-blind, randomised, placebo-controlled trial to evaluate pharmacokinetics, safety and efficacy of single dose of exebacase as add-on to standard of care compared to placebo in children from birth to less than 18 years of age with *Staphylococcus aureus* blood stream infections, including an open-label safety and pharmacokinetic lead-in study

Extrapolation, modelling and simulation studies	2	**Study 3** Modelling and simulation study to evaluate the use of exebacase in the treatment of *Staphylococcus aureus* bacteraemia in children from birth to less than 18 years of age with *Staphylococcus aureus* blood stream infections **Study 4** Extrapolation study to evaluate the use of exebacase in the treatment of *Staphylococcus aureus* bacteraemia in children from birth to less than 18 years of age with *Staphylococcus aureus* blood stream infections
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes